Findings from an open-label trial support the FDA approval of inotuzumab ozogamicin as a treatment for pediatric patients with relapsed/refractory acute lymphoblastic leukemia.
Approval Alert | Inotuzumab Ozogamicin in Pediatric CD22+ ALL
Advertisement
Advertisement
Trending on CancerNetwork
1
Novel T Cell Therapies Yield Decade-Long Remission in Epithelial Cancer
2
Sacituzumab Govitecan Misses PFS End Point in Metastatic Breast Cancer
3
ELI-002 7P Elicits Robust T-Cell Responses in KRAS+ Pancreatic Cancer
4
Mecbotamab Vedotin Shows Positive OS Results in Soft Tissue Sarcoma
5
